Asia Asset Management2d
Has Bain bailed from tussle for Fuji Soft?
The unusually contentious bidding war between US private equity firms Bain Capital and KKR for Tokyo-listed Fuji Soft looks ...
JD Supra4d
Global M&A Trends: Spotlight on Japan
According to a recent KPMG report, the global M&A landscape in 2024 signals a rebound despite challenges like geopolitical tensions, high ...
ENDPOINTS NEWS4d
How Bain’s $3.3B deal for cen­turies-old Tan­abe Phar­ma came to fruition
About two and a half years before they sealed a $3.3 billion deal, Bain Capital and its life sciences team started courting ...
FiercePharma4d
Fierce Pharma Asia—Astellas' investment focus; Mitsubishi Tanabe's buyout; Leqembi's 'expansion phase'
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
U.S. investors, Big Pharma race to find new medicines in China
U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...